RE:RE:RE:Not sure I wanted to bring this topic up (again.)
At this stage I think it would take $2 billion, if after succesful ph1 gbm/nsclc then $6 to $10 billion.
Let's consider Merck's keytruda patents fall off in a few years, maybe they can get it extended. Merck's market cap is $326 billion. Keytruda accounts for 1/3 of sales and probably more than half it's market cap. $2 billion today is not much to protect their revenue stream and probably enhance it considerably. Conversely, lots of other big pharma watching. I would love to see a friendly or hostile bid @ $1.5 this coming week. It would end up being much more before it's done, imo.